Prediction: This Biotech Stock Is Heading for a Once-in-a-Generation Opportunity

Biotech companies have brought many important treatments to market, from ones that address rare diseases to ones that handle common health problems. Vertex Pharmaceuticals (NASDAQ: VRTX) has stood out over the past several years as a top biotech player, thanks to its work in the area of cystic fibrosis (CF). The company's portfolio of treatments is changing the lives of patients and bringing in blockbuster revenue -- in the most recent quarter, product revenue climbed in the double digits to nearly $2.8 billion.In recent years, investors appreciated Vertex's dominance in the CF market, but some worried about the company's focus on only one treatment area. These days, though, Vertex is on the path to eliminating those worries. Earlier this year, it launched a treatment for blood disorders, and today it's about to address one of the world's most common health problems -- a market where need is particularly high. My prediction is that Vertex is heading for a once-in-a-generation opportunity, and investors who get in on the stock today should benefit for years to come. Let's find out more.Image source: Getty Images.Continue readingWeiter zum vollständigen Artikel bei MotleyFool Weiter zum vollständigen Artikel bei MotleyFool